Community Action Needed: Please respond to the NIH RFI
ZFIN ID: ZDB-FISH-150901-13966
Fish name: s843Tg; sd2Tg
Genotype: s843Tg; sd2Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by s843Tg; sd2Tg
No data available
GENE EXPRESSION
Gene expression in s843Tg; sd2Tg
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab7-mapk control Fig. 1 with image from Gong et al., 2017
Ab5-akt control Fig. 1 with image from Gong et al., 2017
Ab1-amotl2a amotl2a standard conditions Fig. 2 with image from Hultin et al., 2017
PHENOTYPE
Phenotype in s843Tg; sd2Tg
Phenotype Conditions Figures
blood decreased fluid flow, abnormal chemical treatment: messenger RNA Fig. 6 with image from Fish et al., 2008
blood circulation decreased process quality, abnormal chemical treatment by environment: tricaine Fig. 2 from Xie et al., 2018
blood circulation decreased process quality, abnormal chemical treatment by environment: nifedipine Fig. 2 from Xie et al., 2018
blood circulation disrupted, abnormal chemical treatment: vatalanib Fig. 5 with image from Fish et al., 2008
blood circulation disrupted, abnormal chemical treatment by environment: lipopolysaccharide Fig. 6 from Philip et al., 2017
blood circulation disrupted, abnormal chemical treatment: messenger RNA Fig. 6 with image from Fish et al., 2008
blood vessel morphogenesis disrupted, abnormal chemical treatment: vatalanib Fig. 5 with image from Fish et al., 2008
brain hemorrhagic, abnormal chemical treatment by environment: warfarin Fig. 5 with image from Hegarty et al., 2013
brain hemorrhagic, ameliorated chemical treatment by injection: phylloquinone, chemical treatment by environment: warfarin Fig. 5 with image from Hegarty et al., 2013
brain hemorrhagic, ameliorated chemical treatment by injection: menaquinone-4, chemical treatment by environment: warfarin Fig. 5 with image from Hegarty et al., 2013
brain vasculature morphology, normal control Fig. 5 from Buchner et al., 2007
caudal vein plexus malformed, abnormal chemical treatment by environment: EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor Fig. 4 from Xie et al., 2018
caudal vein plexus sprouting angiogenesis decreased occurrence, abnormal chemical treatment by environment: EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor Fig. 4 from Xie et al., 2018
cranial blood vessel structure, ameliorated chemical treatment by injection: phylloquinone, chemical treatment by environment: warfarin Fig. 5 with image from Hegarty et al., 2013
cranial blood vessel structure, ameliorated chemical treatment by injection: menaquinone-4, chemical treatment by environment: warfarin Fig. 5 with image from Hegarty et al., 2013
cranial vasculature broken, abnormal chemical treatment: vatalanib Fig. 5 with image from Fish et al., 2008
dorsal aorta decreased width, abnormal chemical treatment by environment: lipopolysaccharide Fig. 6 from Philip et al., 2017
dorsal aorta unlumenized, abnormal chemical treatment: messenger RNA Fig. 6 with image from Fish et al., 2008
dorsal aorta blood circulation disrupted, abnormal chemical treatment by environment: lipopolysaccharide Fig. 6 from Philip et al., 2017
intersegmental vessel unlumenized, abnormal chemical treatment: vatalanib Fig. 5 with image from Fish et al., 2008
nucleate erythrocyte mislocalised, abnormal chemical treatment: messenger RNA Fig. 6 with image from Fish et al., 2008
posterior cardinal vein unlumenized, abnormal chemical treatment: messenger RNA Fig. 6 with image from Fish et al., 2008
posterior cardinal vein blood circulation disrupted, abnormal chemical treatment by environment: lipopolysaccharide Fig. 6 from Philip et al., 2017

CITATIONS  (38)